Our results are in line with those of a smaller study by von Minckwitz et al., in which DCIS was eradicated in 30/59 patients (51%) with HER2-positive IBC who were treated with a neoadjuvant regimen including anthracyclines, taxanes and trastuzumab with or without capecitabine [24]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.